We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Researchers Recommend the Membrane Protein Flotillin as a Biomarker for Alzheimer’s Disease

By LabMedica International staff writers
Posted on 12 Nov 2019
A team of Japanese researchers have suggested adding the protein flotillin to the arsenal of biomarkers that can be used to diagnose Alzheimer’s disease.

Flotillins are membrane proteins that form microdomains in the plasma membrane of all mammalian cell types studied to date. More...
They span the evolutionary spectrum, with proteins related to flotillins present in bacteria, fungi, plants, and metazoans, which suggests that they perform important, and probably conserved, functions. Flotillins have been implicated in myriad processes that include endocytosis, signal transduction, and regulation of the cortical cytoskeleton, yet the molecular mechanisms that underlie flotillin function in these different cases are still poorly understood.

Investigators at Nagoya City University (Japan) had shown previously that flotillin release was reduced by amyloid beta (Abeta), a well known Alzheimer’s disease (AD) biomarker. Therefore, they designed the current study to determine whether flotillin levels would be reduced in the cerebral spinal fluid (CSF) and/or serum of patients with AD.

For this study, the investigators used western blotting to analyze flotillin levels in the CSF and serum of non-AD controls and of patients with AD and mild cognitive impairment (MCI). Flotillin levels in cerebroventricular fluid (CVF) and serum of AD, vascular dementia (VaD), and non-AD autopsy cases were also analyzed.

Results revealed that flotillin levels were significantly lower in the CSF and serum of AD patients compared with those of non-AD controls. Moreover, in patients with MCI due to AD, CSF and serum flotillin levels were significantly decreased compared with those of patients with MCI not due to AD. Flotillin levels remained unchanged in CVF and serum of autopsy cases diagnosed as VaD. Serum flotillin level was negatively associated with deposition of amyloid plaques in the brain.

The investigators postulated that these results, which were published in the October 29, 2019, online edition of the Journal of Alzheimer's Disease, demonstrated that serum flotillin level could serve as one of the blood markers for estimation of brain amyloid deposition and early diagnosis of AD.

Related Links:
Nagoya City University


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Microscope
dIFine
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.